carbon tetrachloride has been researched along with miglustat in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, J; Chiba, T; Fujita, N; Fujiwara, K; Honda, T; Inoue, M; Ishino, T; Iwanaga, T; Kan, M; Kanda, T; Kaneko, T; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kogure, T; Kondo, T; Koroki, K; Kusakabe, Y; Ma, Y; Maruyama, H; Mimura, N; Murayama, T; Muroyama, R; Nakagawa, M; Nakagawa, R; Nakamoto, S; Nakamura, H; Nakamura, M; Ogasawara, S; Ogawa, K; Qiang, N; Sakuma, T; Yumita, S; Zhang, J | 1 |
1 other study(ies) available for carbon tetrachloride and miglustat
| Article | Year |
|---|---|
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.
Topics: Animals; Carbon Tetrachloride; Hepatic Stellate Cells; Humans; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |